Frequency News and Research

RSS

Researchers unveil new method to target and destroy cancerous cells

Using hyperthermia, Virginia Tech engineering researchers and a colleague from India unveiled a new method to target and destroy cancerous cells. The research was presented at the 63rd annual meeting of the American Physical Society Nov. 23 in Long Beach, Calif.

23 Nov 2010

New computer method measures mechanical stress in fat cells

From fad diets to exercise programs, Americans continue to fight the battle of the bulge. Now they'll have help from recent Tel Aviv University research that has developed a new method to look at how fat cells which produce the fat in our bodies respond to mechanical loads.

23 Nov 2010

New simple diagnostic tool to detect dangerous viruses

Boston University researchers have developed a simple diagnostic tool that can quickly identify dangerous viruses like Ebola and Marburg. The biosensor, which is the size of a quarter and can detect viruses in a blood sample, could be used in developing nations, airports and other places where natural or man-made outbreaks could erupt.

22 Nov 2010

Bardoxolone methyl treatment may reduce stage of CKD, improve eGFR in kidney function

Reata Pharmaceuticals and Abbott today announced data from a Phase 2b study which suggests that bardoxolone methyl, an investigational treatment for chronic kidney disease (CKD), may reduce the stage of CKD and improve estimated glomerular filtration rate (eGFR) and other measures of kidney function in the majority of patients receiving the drug.

22 Nov 2010

German researchers use binocular rivalry to interpret mechanism of brain functions

Researchers around Andreas Bartels at the Werner Reichardt Centre for Integrative Neurosciences (CIN) and the Max Planck Institute for Biological Cybernetics in Tübingen, Germany used this phenomenon to decipher a key mechanism of the brain functions that contributes to conscious visual perception.

20 Nov 2010

ENERCA network organizes European Symposium on rare anemias

It is estimated that rare diseases -those whose frequency is under 5 cases / 10,000 people- affect about 6% of the European population. In the field of anemia, 1% of couples are at risk of having a newborn with a severe syndrome of hemoglobin. More than 330,000 children are born worldwide each year affected by one of these diseases, being the most common disorders sickle cell anemia and thalassemia syndromes.

19 Nov 2010

Caprini Risk Model helps predict VTE risk in patients undergoing plastic surgery

Patients undergoing plastic or reconstructive surgery should receive a risk assessment before their procedure to predict whether they'll develop potentially fatal blood clots in the legs or lungs, according to research at the University of Michigan Medical School. Researchers also found that 1 in 9 patients at highest risk based on that assessment will develop clots if not given clot-preventing medications after surgery.

19 Nov 2010

NAVISTAR THERMOCOOL Catheter improves quality of life in patients with atrial fibrillation

According to data appearing today in Circulation Cardiovascular Quality and Outcomes, patients with a common heart rhythm disorder, called atrial fibrillation, who were treated with catheter ablation using the NAVISTAR THERMOCOOL Catheter, reported markedly fewer symptoms and substantially improved quality of life than patients treated with antiarrhythmia drugs at one year.

18 Nov 2010

Neural differences may help explain prevalence of mental disorders in boys

Many mental health disorders, such as autism and schizophrenia, produce changes in social behavior or interactions. The frequency and/or severity of these disorders is substantially greater in boys than girls, but the biological basis for this difference between the two sexes is unknown.

18 Nov 2010

Study finds Hispanic children are susceptible to develop fatty liver disease

Two studies from the Childhood Obesity Research Center at the Keck School of Medicine of the University of Southern California (USC) have found evidence that Hispanic children and adolescents are genetically predisposed to developing fatty liver disease a condition that can lead to cirrhosis, cardiovascular disease and diabetes.

18 Nov 2010

VX-770 drug candidate improves lung function in people with cystic fibrosis

In a study published in this week's New England Journal of Medicine, treatment with a new drug candidate known as VX-770 resulted in improvements in lung function and markers of disease in a Phase 2 clinical trial of 39 people with cystic fibrosis (CF). There were no discontinuations due to adverse events in the study, and the frequency of adverse events was similar across the study groups.

18 Nov 2010

Sangamo presents Phase 2 clinical data in ALS at Society for Neuroscience Meeting

Sangamo BioSciences, Inc. announced today the presentation of Phase 2 clinical data from its ZFP Therapeutic program to develop SB-509, a zinc finger protein transcriptional activator (ZFP-TF) of the vascular endothelial growth factor (VEGF)-A gene as a treatment for ALS.

17 Nov 2010

Targeted therapies could treat a broad range of cancers: Research

Targeted cancer therapies such as trastuzumab (Herceptin), gefitinib (Iressa) and erlotinib (Tarceva) could be used to treat a wider range of cancers than previously thought, according to new research presented today (Wednesday) at the 22nd EORTC-NCI-AACR [1] Symposium on Molecular Targets and Cancer Therapeutics in Berlin.

17 Nov 2010

U-M researcher awarded $600,000 grant for study of progesterone in treatment of children with TBI

A University of Michigan researcher has received a two-year, $600,000 grant to plan a randomized controlled study of progesterone for the treatment of traumatic brain injury in children.

17 Nov 2010

New OncoMap technique can detect point mutation in ovarian cancer

Researchers have shown that point mutations mis-spellings in a single letter of genetic code that drive the onset and growth of cancer cells can be detected successfully in advanced ovarian cancer using a technique called OncoMap. The finding opens the way for personalised medicine in which every patient could have their tumour screened, specific mutations identified, and the appropriate drug chosen to target the mutation and halt the growth of their cancer.

17 Nov 2010

St. Jude Medical and ZONARE enter partnership in ultrasound imaging

St. Jude Medical, Inc., a global medical device company and ZONARE Medical Systems, a leading provider of premium ultrasound systems, today announced they have entered into a development and marketing agreement. Under this agreement, the companies will combine the St. Jude Medical intracardiac echocardiography (ICE) catheter and the ZONARE z.one Convertible Ultrasound system technology, and co-market an ultrasound system for intracardiac (inside the heart) imaging.

17 Nov 2010

Medical Acoustics receives UB CAT/NYSTAR grant

Medical Acoustics LLC, a commercial-stage medical device company which employs acoustic technologies for diagnostic and therapeutic medical applications, today announced that it has been awarded a UB CAT/NYSTAR grant.

16 Nov 2010

New 3M Littmann auscultation device can transfer digitally captured patient sounds

With new technology announced today by 3M, a doctor in Minnesota can in real-time detect a murmur in the heart of a child in rural Arizona. Through the new 3M Littmann Scope-to-Scope Tele-Auscultation System, clinicians can transfer digitally captured patient sounds in real-time, from one stethoscope to another, no matter the distance.

16 Nov 2010

Bayer presents results from Phase III ROCKET AF trial for atrial fibrillation at American Heart Association

Bayer today announced the results from the pivotal, double-blind Phase III, ROCKET AF trial. In the study, rivaroxaban demonstrated superiority to warfarin in reducing the risk of stroke and non-CNS systemic embolism in patients with atrial fibrillation (AF).

16 Nov 2010

ViroPharma presents data on Cinryze C1 esterase inhibitor for HAE at ACAAI Meeting

ViroPharma Incorporated today announced data in four poster presentations and two oral presentations relating to Cinryze (C1 esterase inhibitor [human]) at the 2010 Annual Meeting of the American College of Allergy, Asthma & Immunology (ACAAI), November 11 through 16 in Phoenix, Ariz.

16 Nov 2010

Frequency News and Research

Researchers unveil new method to target and destroy cancerous cells

New computer method measures mechanical stress in fat cells

New simple diagnostic tool to detect dangerous viruses

Bardoxolone methyl treatment may reduce stage of CKD, improve eGFR in kidney function

German researchers use binocular rivalry to interpret mechanism of brain functions

ENERCA network organizes European Symposium on rare anemias

Caprini Risk Model helps predict VTE risk in patients undergoing plastic surgery

NAVISTAR THERMOCOOL Catheter improves quality of life in patients with atrial fibrillation

Neural differences may help explain prevalence of mental disorders in boys

Study finds Hispanic children are susceptible to develop fatty liver disease

VX-770 drug candidate improves lung function in people with cystic fibrosis

Sangamo presents Phase 2 clinical data in ALS at Society for Neuroscience Meeting

Targeted therapies could treat a broad range of cancers: Research

U-M researcher awarded $600,000 grant for study of progesterone in treatment of children with TBI

New OncoMap technique can detect point mutation in ovarian cancer

St. Jude Medical and ZONARE enter partnership in ultrasound imaging

Medical Acoustics receives UB CAT/NYSTAR grant

New 3M Littmann auscultation device can transfer digitally captured patient sounds

Bayer presents results from Phase III ROCKET AF trial for atrial fibrillation at American Heart Association

ViroPharma presents data on Cinryze C1 esterase inhibitor for HAE at ACAAI Meeting

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News